Clinipace buys regulatory affairs unit
Clinipace Worldwide has bought Regulus Pharmaceutical Consulting to add regulatory expertise to its eClinical contract research services business.
CMO consolidation will support 100% virtual supply chains
Consolidation of CMOs will support use of completely outsourced production and distribution networks in the near future.
Numira Biosciences acquires Ricerca's Bothell lab operations
US-based Numira Biosciences has expanded its imaging and pre-clinical services portfolio after acquiring the efficacy pharmacology operating unit of Ricerca Biosciences.
QPS buys tox and preclinical testing capacity in Taiwan
QPS Holdings has acquired Taiwan’s Center of Toxicology and Preclinical Sciences (CTPS), continuing its expansion in the region’s rapidly expanding drug development sector.
Increasingly bold outsourcing will help big pharma cut costs
Big pharma outsourcing will become much bolder in the next 12-18 months as companies attempt to “dramatically attack cost structures”, according to the Covance CEO.
inVentiv to buy i3 & Campbell Alliance
inVentiv Health is to acquire i3 and Campbell Alliance and realign into three operating units: clinical, consulting and commercial.
CRI acquires Lifetree to expand Phase I capabilities
CRI Worldwide has acquired Lifetree Clinical Research to double its Phase I capacity and expand therapeutic expertise.
Icon buys Oxford Outcomes to boost Ph IV biz
Dublin, Ireland-based contract research organisation (CRO) Icon has bought Oxford Outcomes, expanding its late Phase research business.
AMRI merges discovery units
AMRI has combined its discovery R&D and chemistry units into a single unit it claims will benefit customers.
Top 5 consolidation, cutback & closure articles of 2010
The contract service market failed to recover as hoped in 2010 and consequently many companies made cutbacks. Outsourcing-Pharma rounds up five of the most read of 2010.
Top strategic partnership news on Outsourcing-Pharma
Outsourcing-Pharma presents a round up five of our top articles on strategic partnering, which continued apace in 2010, including deals by Covance, PPD and Parexel.
PRA consolidates in Poland to support growth, contain costs
PRA has relocated its Poland-based early development services and product registration teams into a larger shared office after achieving “solid increases in the placement of clinical studies”.
Cardinal Health acquires Chinese distributer as part of new ‘growth platform’
US based healthcare distributer, Cardinal Health, has announced the $470m acquisition of privately held healthcare distribution business Zuellig Pharma China, known locally as Yong Yu.
Kendle op profit down 64% as early stage review nears end
Kendle recorded a 64 per cent drop in Q3 operating income and expects its strategic review of early stage, which will establish a fair value and consider all options, to be complete next quarter.
Southern Research gains bioanalytical lab assets in BioCryst acquisition
Southern Research Institute is acquiring BioCryst Pharmaceuticals’ bioanalytical laboratory assets and personnel in a move towards expanding its bioanalytical service offerings.
BioClinica shareholder calls for managment resignations
BioClinica shareholder Nicusa Capital is calling for the resignation of CEO Mark Weinstein, CFO Ted Kaminer and Chairman David Nowiki, after describing the firm’s corporate strategy as “defective.”
Covance & Sanofi ink 10-year, $2.2bn strategic R&D alliance
Covance has inked a 10-year strategic alliance, worth up to $2.2bn, with Sanofi-Aventis and acquired two European sites from the big pharma.
DSM seeks Asian partners; welcomes J&J Crucell takeover
DSM aims to keep pace with the rapid evolution of pharmaceutical sector through increased partnering and a focus on Asia.
ImmunoSolv & GBC merge; plan contract services growth
ImmunoSolv is merging with Grampian BioConsultants (GBC) and plans to accelerate development of the contract research business.
Encorium cuts Q2 operating loss despite drop in revenue
Encorium cut its operating loss to $775,000 in the second quarter despite posting a 17 per cent drop in total revenue.
Cyprotex sees profits down in H1, but predicts US growth
Pre-clinical ADME contractor Cyprotex upbeat about 2010 despite drop in profit, citing new US opportunities post-Apredica acquisition.
Contract research organization (CRO) Lambda Therapeutic Research has acquired Biovail’s contract research division.
AMRI posts $6m operating loss in Q2; plans expansions
AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
Bilcare to boost EU and US access with €100m Ineos Films buy
Bilcare to buy Ineos’ rigid polymer films business for €100m ($132m) to improve access to pharmaceutical packaging customers worldwide.
CRL & WuXi discuss Q2 results, life after collapse of deal
CRL and WuXi have both vowed to independently build their capabilities, to become integrated service providers, but reported mixed financial results.
CRL abandons Wuxi takeover after shareholder opposition
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
Pharma consolidation and the downstream impact on CROs
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Icon op income down; “pretty active” in pursuit of M&A
Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future.
Encorium buys Progenitor for vacc biz and global reach
Encorium has bought Progenitor International Research, furthering efforts to fix its financial woes by focusing on vaccines, oncology and growth in emerging markets.
Jana says Wuxi deal offers inadequate returns for CRL
Major Charles River Laboratories (CRL) shareholder Jana Partners says Wuxi PharmaTech deal would generate inadequate returns, citing “industry” concerns about integration.
CRL cites WuXi synergies, client support to woo investors
CRL has said the WuXi buy could add up to $100m (€78m) in additional annual revenue and spoken of clients’ enthusiasm for the deal as its attempts to shore up investor support.
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys...
Sanofi looks to sell EU research sites to Covance
Sanofi Aventis intends to sell two of its European research facilities to US-based contract research organisation (CRO) Covance.
Aptuit to acquire GSK’s Italian R&D centre
Aptuit is to acquire GSK’s Italian R&D centre, take on its 500 employees and become part of the big pharma’s CRO network.
Minapharm buys CMO ProBioGen for €30.4m
Egypt-based Minapharm has acquired 95 per cent of CMO ProBioGen for a possible total of €30.4m ($37.6m).
Icon and Parexel partner with B-MS to support clinical dev
Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.
Patheon op profit up 12%
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
Know your Lilly from your Lonza? Then test your industry knowledge against colleagues, peers and our community of readers by participating in our exclusive map-based quiz.
CRL shareholder criticises and opposes WuXi deal
CRL shareholder Jana Partners has said the attempt to buy WuXi PharmaTech is the “wrong path” and it will vote against the deal.
Novella buys Prologue to strengthen oncology services
US-based contract research organisation (CRO) Novella Clinical has acquired Prologue Research to enhance its offering of oncology clinical trial services.
Surya raising funds to invest in production capacity
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
i3 hopes ChinaGate opens path to regulatory success
i3 has bought contract regulatory services firm ChinaGate to build in China’s rapidly expanding drug and device clinical research market.
WuXi Q1 lab biz grows, good news for potential new owner CRL
Continued strong demand for laboratory services and improved manufacturing division performance helped Wuxi PharmaTech to grow in Q1.
ERT buys CRS adding respiratory diagnostics to offering
Cardiac monitoring and ePRO specialist ERT has added respiratory diagnostics and device manufacturing services to its offering with the acquisition of CareFusion Research Services (CRS) for $81m (€61m).
Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.
Medpace buys device testing firm Symbios
US CRO Medpace has move into medical device trials with acquisition of Symbios Clinical in a bid to tap into what CEO August Troendle said was a growth area for the contract research sector.
Oracle to buy Phase Forward $685m
IT giant Oracle will pay $685m (€507m) for eClinical solutions firm Phase Forward, significantly expanding its presence in the billion dollar contract clinical research sector.
Clearstone expands Toronto site but is closing NJ lab
Clearstone is expanding safety and esoteric capacity at its laboratory in Toronto, Canada, allowing it to close its facility in New Jersey, US and consolidate North American operations.
IRL and Epichem partner to serve Australasian market
IRL and Epichem have entered into a strategic alliance to provide the Australasian pharma market with services from drug discovery through to cGMP production.
The capabilities of the MDS Pharma Services' sites Ricerca is set to acquire "perfectly dovetail" with its existing capacity, according to a company vice president.